Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

Expert Discusses Toxicity Results in CARD Study

ARASH REZAZADEH KALEBASTY, MD
Sunday, October 06, 2019


The phase IV clinical trial known as the CARD study presented new findings at the European Society of Medical Oncology (ESMO) 2019 congress. The trial compared the chemotherapy agent cabzitaxel (Jevtana) and an androgen receptor, either abiraterone (Zytiga) or enzalutamide (Xtandi), in a randomized group of patients with advanced prostate cancer.

The results proved promising for treating advanced prostate cancer with manageable toxicity. At ESMO OncLive®, a sister publication of Oncology Nursing News® had the chance to sit down with Arash Rezazadeh Kalebasty, MD, medical oncologist at the Norton Cancer Institute, to discuss the findings of the CARD study in relation to toxicity.
    

TRANSCRIPTION

One important outcome was grade 3 and more toxicity, which was not really very much higher than the androgen therapy arm. I think it's very encouraging because in this patient population toxicity matters as a lot of patients with advanced prostate cancer are elderly. So, specifics for this trial had excluded patients who were not a good candidate for chemotherapy anyways, but we have to be careful about benefit versus risk when we offer patients chemotherapy as well. 
 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.